SCHEMBL2804514

SCHEMBL2804514

COC(=O)c1ccc(Br)c(OCCCO[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.41
TTR P02766 1/20 0.40
MAPT P10636 3/20 0.38
SMPD1 P17405 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
XDH P47989 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
ALOX15 P16050 2/20 0.35
HTT P42858 1/20 0.35
REN P00797 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13125216 0.83 MAPT (0.44) MAPTRAB9AKMT2AKDM4EMEN1
SCHEMBL3081455 0.83 TSHR (0.40) TTRMAPTCA12CA1CA2
SCHEMBL31662691 0.82 TTR (0.43) NOTUMTTRMAPTSMPD1L3MBTL1
SCHEMBL2934404 0.82 KDM4E (0.46) NOTUMTTRMAPTSMPD1L3MBTL1
SCHEMBL17129512 0.82 NOTUM (0.42) NOTUMTTRMAPTSMPD1L3MBTL1
SCHEMBL20605050 0.81 SMN1; SMN2 (0.49) MAPTL3MBTL1HTTRAB9AKMT2A
SCHEMBL18054821 0.81 CA12 (0.47) TTRMAPTSMPD1L3MBTL1TDP1
SCHEMBL1628037 0.80 MAPT (0.62) MAPTL3MBTL1TDP1CA1CA2
SCHEMBL26814603 0.80 CYP1A2 (0.44) NOTUMTTRMAPTL3MBTL1TDP1
SCHEMBL14930286 0.79 ESR1 (0.52) NOTUMMAPTSMPD1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 NOTUM 954/4885TTR 860/4885MAPT 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.